Cellebrite Di Stock Analysis
CLBT Stock | USD 14.20 0.18 1.25% |
Cellebrite DI is undervalued with Real Value of 15.69 and Target Price of 24.57. The main objective of Cellebrite stock analysis is to determine its intrinsic value, which is an estimate of what Cellebrite DI is worth, separate from its market price. There are two main types of Cellebrite's stock analysis: fundamental analysis and technical analysis.
The Cellebrite stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Cellebrite is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Cellebrite Stock trading window is adjusted to America/New York timezone.
Cellebrite | Build AI portfolio with Cellebrite Stock |
Cellebrite Stock Analysis Notes
About 46.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.92. Cellebrite DI had not issued any dividends in recent years. Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Cellebrite Mobile Synchronization Ltd. operates as a subsidiary of Sun Corporation. Cellebrite operates under SoftwareInfrastructure classification in the United States and is traded on NASDAQ Exchange. It employs 900 people. For more info on Cellebrite DI please contact Yossi Carmil at 972 73 394 8000 or go to https://www.cellebrite.com.Cellebrite Quarterly Total Revenue |
|
Cellebrite DI Investment Alerts
Cellebrite DI generated a negative expected return over the last 90 days | |
Cellebrite DI has high likelihood to experience some financial distress in the next 2 years | |
The company reported the previous year's revenue of 401.2 M. Net Loss for the year was (283.01 M) with profit before overhead, payroll, taxes, and interest of 352.35 M. | |
About 46.0% of the company shares are held by company insiders | |
Latest headline from finance.yahoo.com: Cellebrite DI Expands its Partnership NCMEC |
Cellebrite DI Upcoming and Recent Events
15th of February 2024 Upcoming Quarterly Report | View | |
8th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
15th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Cellebrite Largest EPS Surprises
Earnings surprises can significantly impact Cellebrite's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2025-05-14 | 2025-03-31 | 0.09 | 0.1 | 0.01 | 11 | ||
2023-05-10 | 2023-03-31 | 0.02 | 0.03 | 0.01 | 50 | ||
2023-02-15 | 2022-12-31 | 0.07 | 0.08 | 0.01 | 14 |
Cellebrite Environmental, Social, and Governance (ESG) Scores
Cellebrite's ESG score is a quantitative measure that evaluates Cellebrite's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Cellebrite's operations that may have significant financial implications and affect Cellebrite's stock price as well as guide investors towards more socially responsible investments.
Cellebrite Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Crosslink Capital Inc | 2025-03-31 | 2.2 M | Nine Ten Capital Management Llc | 2025-03-31 | 2 M | Bank Of America Corp | 2025-03-31 | 1.9 M | Pembroke Management Ltd | 2025-03-31 | 1.8 M | Two Sigma Advisers, Llc | 2025-03-31 | 1.7 M | Greenhaven Road Investment Management, L.p. | 2025-03-31 | 1.6 M | Handelsbanken Fonder Ab | 2025-03-31 | 1.5 M | Meitav Dash Investments Ltd | 2025-03-31 | 1.5 M | Ashford Capital Management Inc | 2025-03-31 | 1.2 M | True Wind Capital Management, L.p. | 2025-03-31 | 13.9 M | Fmr Inc | 2025-03-31 | 9.9 M |
Cellebrite Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.44 B.Cellebrite Profitablity
The company has Profit Margin (PM) of (0.46) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.11 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.11.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.44) | (0.41) | |
Return On Capital Employed | 0.14 | 0.15 | |
Return On Assets | (0.41) | (0.39) | |
Return On Equity | (0.84) | (0.88) |
Management Efficiency
Cellebrite DI has return on total asset (ROA) of 0.0605 % which means that it generated a profit of $0.0605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1535) %, meaning that it created substantial loss on money invested by shareholders. Cellebrite's management efficiency ratios could be used to measure how well Cellebrite manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.15 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (0.41). Non Current Liabilities Total is likely to gain to about 122.9 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 220.4 M in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 1.60 | 1.68 | |
Tangible Book Value Per Share | 1.41 | 1.48 | |
Enterprise Value Over EBITDA | 65.68 | 62.39 | |
Price Book Value Ratio | 13.73 | 14.41 | |
Enterprise Value Multiple | 65.68 | 62.39 | |
Price Fair Value | 13.73 | 14.41 | |
Enterprise Value | 1.7 B | 1.5 B |
Cellebrite's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Technical Drivers
As of the 22nd of July, Cellebrite shows the Risk Adjusted Performance of (0.18), standard deviation of 2.25, and Mean Deviation of 1.6. Cellebrite DI technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cellebrite DI Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Cellebrite for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Cellebrite DI short-term fluctuations and highlight longer-term trends or cycles.
Cellebrite Outstanding Bonds
Cellebrite issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cellebrite DI uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cellebrite bonds can be classified according to their maturity, which is the date when Cellebrite DI has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
MGM Resorts International Corp BondUS552953CD18 | View | |
Valero Energy Partners Corp BondUS91914JAA07 | View |
Cellebrite Predictive Daily Indicators
Cellebrite intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cellebrite stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Accumulation Distribution | 53186.87 | |||
Daily Balance Of Power | (0.33) | |||
Rate Of Daily Change | 0.99 | |||
Day Median Price | 14.43 | |||
Day Typical Price | 14.35 | |||
Price Action Indicator | (0.32) | |||
Period Momentum Indicator | (0.18) |
Cellebrite Corporate Filings
6K | 8th of July 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 5th of June 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
6K | 14th of May 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
12th of May 2025 Other Reports | ViewVerify | |
20th of March 2025 Other Reports | ViewVerify | |
18th of March 2025 Other Reports | ViewVerify | |
6K | 13th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
12th of February 2025 Other Reports | ViewVerify |
Cellebrite Forecast Models
Cellebrite's time-series forecasting models are one of many Cellebrite's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cellebrite's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Cellebrite Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Cellebrite prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cellebrite shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cellebrite. By using and applying Cellebrite Stock analysis, traders can create a robust methodology for identifying Cellebrite entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.69) | (0.65) | |
Operating Profit Margin | 0.14 | 0.15 | |
Net Loss | (0.71) | (0.67) | |
Gross Profit Margin | 0.84 | 0.66 |
Current Cellebrite Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cellebrite analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cellebrite analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
24.57 | Strong Buy | 8 | Odds |
Most Cellebrite analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cellebrite stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cellebrite DI, talking to its executives and customers, or listening to Cellebrite conference calls.
Cellebrite Stock Analysis Indicators
Cellebrite DI stock analysis indicators help investors evaluate how Cellebrite stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cellebrite shares will generate the highest return on investment. By understating and applying Cellebrite stock analysis, traders can identify Cellebrite position entry and exit signals to maximize returns.
Begin Period Cash Flow | 189.5 M | |
Total Stockholder Equity | 336 M | |
Capital Lease Obligations | 11 M | |
Property Plant And Equipment Net | 27.6 M | |
Cash And Short Term Investments | 447.2 M | |
Cash | 191.7 M | |
50 Day M A | 16.4116 | |
Net Interest Income | -331.5 M | |
Total Current Liabilities | 295.5 M | |
Forward Price Earnings | 37.1747 | |
Investments | -149.5 M | |
Interest Expense | 349.8 M | |
Stock Based Compensation | 30.6 M | |
Common Stock Shares Outstanding | 209.5 M | |
Total Cashflows From Investing Activities | -149.5 M | |
Tax Provision | 7 M | |
Quarterly Earnings Growth Y O Y | -0.769 | |
Other Current Assets | 27.7 M | |
Accounts Payable | 11.1 M | |
Net Debt | -180.7 M | |
Other Operating Expenses | 344.3 M | |
Non Current Assets Total | 123 M | |
Liabilities And Stockholders Equity | 690.6 M | |
Non Currrent Assets Other | 7.7 M |
Additional Tools for Cellebrite Stock Analysis
When running Cellebrite's price analysis, check to measure Cellebrite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellebrite is operating at the current time. Most of Cellebrite's value examination focuses on studying past and present price action to predict the probability of Cellebrite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellebrite's price. Additionally, you may evaluate how the addition of Cellebrite to your portfolios can decrease your overall portfolio volatility.